ACAD ACADIA Pharmaceuticals Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 07 October 2019 ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress

   — Pimavanserin as adjunctive treatment to SSRI/SNRI therapies significantly improved sexual dysfunction symptoms compared to placebo in MDD patients ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that based

2. 03 October 2019 ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer's Disease (CTAD) 2019 Meeting

   ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the presentation of the results from the Phase 3 HARMONY study of pimavanserin in dementia-related psychosis has been accepted for a late-breaking oral

3. 25 September 2019 ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019

   ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today

4. 24 September 2019 ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder

   - Pimavanserin as an adjunctive treatment for patients with MDD showed significant overall improvement in HAMD-17 total score compared to placebo - Phase 3 CLARITY program initiated in April 2019 ACADIA

5. 23 September 2019 ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson's Disease and Movement Disorders

   - Pimavanserin as monotherapy or adjunct to SSRI/SNRI therapies significantly improved depression symptoms for Parkinson's patients ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today announced positive results from an

6. 20 September 2019 ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

   ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,

7. 19 September 2019 ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings

   — New data presented at the International Congress of Parkinson's Disease and Movement Disorders will highlight treatment benefit of pimavanserin in patients with comorbid Parkinson's disease and depression — New data

8. 17 September 2019 ACADIA Pharmaceuticals Prices Public Offering of Common Stock

   ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,

9. 17 September 2019 ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock

   ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,

10. 10 September 2019 Thinking about buying stock in Acadia Pharmaceuticals, Aurora Cannabis, Bank of America, SINTX Technologies, or AT&T?

    NEW YORK, Sept. 9, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACAD, ACB, BAC, SINT, and T. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

11. 09 September 2019 ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis

    - Pimavanserin achieved robust statistical superiority over placebo in time to relapse of dementia-related psychosis at planned interim efficacy analysis - Pimavanserin has the potential to be the first FDA-approved

12. 04 September 2019 ACADIA Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 11, 2019

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today